Pfizer stock price

Pfizer latest news:


  • 02/12/2018 19:34:23

    U.S. investment adviser gets prison for insider trading on Pfizer-King deal

    A Long Island, New York, investment adviser was sentenced to six months in prison on Monday after he pleaded guilty to insider trading in connection with Pfizer Inc's $3.6 billion acquisition of King Pharmaceuticals Inc. Tibor Klein, 44, was sentenced by U.S. District Judge Joan Azrack in the federal court in Brooklyn, New York, according to federal prosecutors.

  • 02/05/2018 15:00:22

    Pfizer's Xtandi delays prostate cancer spread in early stage disease

    Use of Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone, study results that could lead to significantly increased sales of the Pfizer Inc (PFE) and Astellas Pharma Inc (ALPMF) medicine.

  • 01/31/2018 07:05:05

    Title: Top Analyst Upgrades and Downgrades: AK Steel, Apple, Biogen, EA, FitBit, Foot Locker, McDonald’s, Pfizer and Many More


  • 01/30/2018 14:01:30

    UnitedHealth, Pfizer Tank the DJIA Tuesday


  • 01/30/2018 13:25:17

    Pfizer's new tax rate higher than investors hoped, shares fall

    (Reuters) - Pfizer Inc said on Tuesday it expected to pay tax at an adjusted rate of about 17 percent this year, higher than some investors had expected, sending its shares down more than 3 percent.

  • 01/30/2018 12:41:05

    UPDATE 5-Pfizer's new tax rate higher than investors hoped, shares fall

    Jan 30 (Reuters) - Pfizer Inc said on Tuesday it expected to pay tax at an adjusted rate of about 17 percent this year, higher than some investors had expected, sending its shares down more than 3 percent.

  • 01/30/2018 10:40:15

    Pfizer sees upbeat 2018 on lower tax rate, shares dip after highs

    (Reuters) - Pfizer Inc forecast 2018 profit and revenue well ahead of analysts' estimates on Tuesday as it expects to benefit from reduced tax rate following the recent changes to the U.S. tax code, and recorded an $11 billion gain from the overhaul.

  • 01/30/2018 06:50:58

    Pfizer profit tops estimates, books $11 billion tax gain

    (Reuters) - Pfizer Inc beat analysts' estimate for adjusted profit on Tuesday, helped by strong demand for its pneumonia vaccine Prevnar and rheumatoid arthritis drug Xeljanz, while reporting an $11 billion gain from the new tax law.

  • 01/30/2018 05:05:49

    Pfizer shares rise after Q4 profit, revenue beats; upbeat guidance

    Pfizer Inc. shares rose 1.4% in premarket trade Tuesday after the company reported fourth-quarter profit and revenue beats and upbeat 2018 guidance. Earnings for the latest quarter rose rose to $12.27 billion, or $2.02 per share, from $775 million, or 13 cents per share in the year-earlier period. Adjusted earnings-per-share were 62 cents, compared with the FactSet consensus of 56 cents. Revenue rose to $13.70 billion from $13.63 billion, compared with the FactSet consensus of $13.67 billion. The latest results include "continued strength" from products such as Ibrance, Eliquis and Xeljanz, Chief Executive Ian Read said. The company's Essential Health business had strong revenue growth in emerging markets and biosimilars but was hurt by the company's Hospira Infusion Systems divestitute, expected losses of exclusivity for products and Hospira U.S. product shortages, Read said. Pfizer expects 2018 revenue of $53.5 billion to $55.5 billion, compared with the FactSet consensus of $53.82 billion, and 2018 adjusted EPS of $2.90 to $3.00, compared with the FactSet consensus of $2.78. The company said its 2018 financial guidance for the effective tax rate on adjusted income, which it expects to be about 17%, reflects corporate tax reform; Pfizer expects a "meaningfully lower" effective tax rate this year and repatriation tax liability of about $15 billion over eight years. Pfizer also said its 2018 adjusted EPS expectations include an expected $5 billion in share buybacks, and touted its U.S. investments, including plans to invest about $5 billion in capital projects in the U.S. Company shares have surged 11% over the last three months, compared with a 10.9% rise in the S&P 500 and a 13.2% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/26/2018 14:01:21

    Intel, Pfizer Drive DJIA Surge Higher on Friday


  • 01/24/2018 09:05:12

    UPDATE 2-Pfizer's biosimilar of Roche's Rituxan succeeds in study

    Jan 24 (Reuters) - Pfizer Inc said on Wednesday its biosimilar of Roche's Rituxan was as effective as the original drug in treating patients with a type of follicular lymphoma, meeting the main goal of a study.

  • 01/23/2018 12:01:47

    UPDATE 2-U.S. appeals court upholds ruling invalidating J&J patent on Remicade

    Jan 23 (Reuters) - A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

  • 01/23/2018 09:14:45

    U.S. appeals court upholds ruling invalidating J&J patent on Remicade

    A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson (JNJ) patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc (PFE) over its launch of a lower-cost version of the drug.

  • 01/23/2018 09:14:29

    UPDATE 1-U.S. appeals court upholds ruling invalidating J&J patent on Remicade

    Jan 23 (Reuters) - A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

  • 01/09/2018 13:12:38

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Jan 9 (Reuters) - GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

  • 01/08/2018 10:37:05

    Pfizer Halts Research Efforts Into Alzheimer's And Parkinson's Treatments

    The pharmaceutical giant said it would be abandoning its neuroscience development programs and allocating its spending elsewhere. The move also means the company will be laying off some 300 employees.

  • 01/07/2018 12:49:45

    Pfizer ends research for new Alzheimer's, Parkinson's drugs

    NEW YORK, Jan 7 (Reuters) - Pfizer Inc is abandoning research to find new drugs aimed at treating Alzheimer's and Parkinson's disease, the U.S. pharmaceutical company announced on Saturday.

  • 01/03/2018 08:45:58

    Sangamo Jumps on Newest Pfizer Collaboration


  • 12/21/2017 11:20:18

    BRIEF-Pfizer Announces Breakthrough Therapy Designation For Avelumab In Combination With Inlyta

    Pfizer Inc(PFE): * FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA. * PFIZER - BREAKTHROUGH THERAPY DESIGNATION IS BASED ON PRELIMINARY EVALUATION OF CLINICAL DATA FROM JAVELIN RENAL 100 STUDY Source text for Eikon: Further company coverage:

  • 12/19/2017 14:50:27

    Pfizer, Exelixis cancer drugs get FDA approval for wider use

    Cancer treatments from Pfizer Inc (PFE) and Exelixis Inc (EXEL) on Tuesday won approval from the U.S. Food and Drug Administration for expanded use in previously untreated patients. Pfizer's Bosulif was expanded to treat newly-diagnosed adult patients with a rare, chronic form of blood cancer.

  • 12/19/2017 14:16:19

    BRIEF-FDA Approves Pfizer's Bosulif To Treat A Type of Leukemia

    Pfizer Inc(PFE): * U.S. FDA APPROVES PFIZER’S BOSULIF® FOR THE TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA Source text for Eikon: Further company coverage:

  • 12/18/2017 10:31:14

    UPDATE 1-Pfizer announces new $10 bln share buyback, hikes dividend

    Dec 18 (Reuters) - Pfizer Inc said on Monday its board had authorized a new $10 billion share repurchase program and raised its quarterly dividend.

  • 12/18/2017 10:00:51

    Pfizer announces new $10 bln share buyback, hikes dividend

    Pfizer Inc(PFE) said on Monday its board had authorized a new $10 billion share repurchase program and raised its quarterly dividend. The share buyback is in addition to the $6.4 billion remaining under the company's current authorization, Pfizer said. The drugmaker hiked its first-quarter dividend to 34 cents per share from 32 cents.

  • 12/18/2017 09:58:23

    Pfizer sets new $10 billion stock buyback program, bumps up dividend by 6.3%

    Shares of Pfizer Inc. edged up 0.3% in midday trade Monday, after the drug giant said it authorized a new $10 billion share repurchase program, and that it will raise its quarterly cash dividend by 6.3%. Pfizer said the new buyback program is in addition to the $6.4 billion remaining under the current repurchase program. Based on current share prices and 5.96 billion shares outstanding, $16.4 billion would represent 439.7 million shares, or about 7.4% of the shares outstanding. The new dividend of 34 cents a share, up from 32 cents a share, will be payable March 1 to shareholders of record on Feb. 2. The new annual dividend rate implies a dividend yield of 3.65%, compared with the implied yield for the SPDR Health Care Select Sector ETF of 1.45%, and for the Dow Jones Industrial Average of 2.07%. Pfizer's stock has rallied 14.8% year to date, while the health care ETF has run up 21.9% and the Dow has climbed 25.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/15/2017 15:05:34

    Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion

    Pfizer Inc PFE announced that the FDA has approved a label expansion for its janus kinase JAK inhibitor Xeljanz tofacitinib for two doses 5 mg twice daily and 11 mg once daily extended release XR formulation With this latest approval Xeljanz can now be administered for

  • 12/14/2017 18:13:33

    UPDATE 1-Pfizer's Xeljanz gets FDA nod as joint disease treatment

    Dec 14 (Reuters) - U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for treatment of a joint disease.

  • 12/14/2017 17:51:06

    Pfizer's Xeljanz gets FDA nod as joint disease treatment

    Dec 14 (Reuters) - U.S. drugmaker Pfizer Inc said on Thursday the United States Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for the treatment of a joint disease.

  • 12/14/2017 17:42:37

    BRIEF-Pfizer Announces FDA Approval Of Xeljanz® And Xeljanz® Xr For Treatment Of Active Psoriatic Arthritis

    * PFIZER ANNOUNCES FDA APPROVAL OF XELJANZ® (TOFACITINIB) AND XELJANZ® XR FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS

  • 12/13/2017 16:27:11

    BRIEF-FDA Approves Pfizer's New Biosimilar To Remicade

    Pfizer Inc(PFE): * FDA APPROVES NEW PFIZER BIOSIMILAR. * Pfizer Inc(PFE) - UNITED STATES FOOD AND DRUG ADMINISTRATION HAS APPROVED IXIFI AS A BIOSIMILAR TO REMICADE Source text for Eikon: Further company coverage:

  • 12/13/2017 09:05:58

    Why Cellectis Is Winning Big With Its Pfizer Partnership


  • More trends:

    Pharmerica CorporationPMC | PHH CorpPHH | Philip Morris International IncPM | Philippine Long Distance Telephone CompanyPHI | Phillips 66PSX | Phillips 66 Partners LPPSXP | Phoenix CompaniesPFX | Phoenix CompaniesPNX | Phoenix New Media LimitedFENG | Physicians Realty TrustDOC |